Dennis M. Lanfear is CEO & President at Coherus Oncology, Inc. (CHRS). They have made 8 open-market trades across 1 company since 2015, most recently 2026-01-23.
CIK 0001420822
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CHRS | SELL | 2023-11-22 | 2023-11-24 | $2.02 | $451K | +11.2% | +5.8% | +19.9% |
| CHRS | SELL | 2021-06-08 | 2021-06-08 | $13.56 | $842K | +4.1% | -1.3% | +11.0% |
| CHRS | SELL | 2019-11-21 | 2019-11-25 | $18.56 | $464K | -4.8% | -2.6% | +13.7% |
| CHRS | SELL | 2019-11-20 | 2019-11-22 | $18.00 | $14.8M | -6.3% | -2.7% | +20.0% |
| CHRS | SELL | 2019-05-30 | 2019-05-31 | $19.49 | $1.3M | -5.6% | +18.7% | +15.3% |
| CHRS | SELL | 2018-05-16 | 2018-05-17 | $16.26 | $682K | -3.4% | -5.0% | +14.6% |
| CHRS | SELL | 2016-09-20 | 2016-09-22 | $31.75 | $256K | -17.6% | -0.2% | -9.3% |
| CHRS | SELL | 2016-09-16 | 2016-09-20 | $31.79 | $92K | -15.3% | -3.9% | -12.1% |
| CHRS | SELL · 10b5-1 | 2015-11-30 | 2015-12-02 | $31.75 | $13K | -37.4% | -6.3% | -33.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.